Karen Vanhoorelbeke obtained her PhD in Biochemistry in November 1996 at the KU Leuven (Leuven, Belgium) in the Laboratory of Biochemistry of prof dr G. Préaux.
During her PhD she studied the broad spectrum protease inhibitor a2-macroglobulin in the common cuttlefish Sepia officinalis and specialized in molecular biology. After her PhD she moved to the Laboratory for Thrombosis Research at KU Leuven, Kulak (Kortrijk, Belgium) to perform postdoctoral research in the field of thrombosis and haemostasis.
In 2003 she obtained her FWO (Fonds voor Wetenschappelijk Onderzoek Vlaanderen) postdoctoral fellowship and in 2007 she was appointed as an associated professor at the Faculty of Sciences KU Leuven, Kulak. Since then she started her own research group in the laboratory for Thrombosis Research focusing on the hemostatic proteins van Willebrand factor (VWF) and its cleaving enzyme ADAMTS13 and their role in health and disease.
She is also cofounder of PharmAbs, the KU Leuven Antibody Center that focuses on characterization, development and production of antibody-based molecules. PharmAbs has created a state-of-the-art antibody technology platform open for co-development projects with KU Leuven disease biology groups, as well as for contract research collaborations with industrial partners.
Karen Vanhoorelbeke is (co)author of over 120 papers in international peer reviewed journals and is co-owner of 2 patents. An up-to-date list of publications by Prof. Dr. Karen Vanhoorelbeke can be found via Pubmed or via Lirias.